Induction of Oral Immune Tolerance Enables Sequential AAV9/AAV8 Gene Therapy in Mucopolysaccharidosis IVA
International Journal of Molecular Sciences · 2026
DOI: 10.3390/ijms27219553 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Sampurna Saikia und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Oregon Health and Science University, Portland, OR 97239, USA. Hauptthemen laut MEDLINE: Mucopolysaccharidosis IV, Genetic Therapy, Dependovirus, Immune Tolerance. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NICHD NIH HHS, NIH HHS, Austrian MPS Society.
Abstract (Originalsprache)
Mucopolysaccharidosis IVA (MPS IVA) results from deficiency of N-acetylgalactosamine-6-sulfate sulfatase (GALNS), leading to progressive keratan sulfate accumulation, and current treatments have limited efficacy. Although adeno-associated virus (AAV) gene therapy can restore systemic enzyme activity, immune responses to the transgene and viral capsid restrict durability and prevent vector re-administration. We evaluated a combined strategy of antigen-specific oral immune tolerance and sequential AAV serotype delivery. Neonatal MPS IVA mice received a mixture of three immunodominant GALNS-derived T- and B-cell epitopes on alternate days for 20 days, followed by AAV9 at 4 weeks and redosing with either AAV9 or AAV8 at 10 weeks. Peptide-treated tolerized MPS IVA mice showed a 2–3-fold increase in circulating GALNS activity after the first dose and a 7–8-fold increase after redosing, whereas non-tolerized MPS IVA mice developed anti-GALNS antibodies that reduced enzyme levels. No cross-reactive neutralizing antibodies were detected between AAV9 and AAV8. Peptide-treated mice showed normalization of plasma and hepatic keratan sulfate (KS) and significant improvements in skeletal and cardiac histopathology, with the greatest benefit in the peptide-treated AAV9→AAV8 group. These findings demonstrate that oral immune tolerance enables safe AAV re-administration, enhances systemic enzyme bioavailability, and improves tissue correction, supporting a clinically translatable approach for durable treatment of MPS IVA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Oregon Health and Science University, Portland, OR 97239, USA.
- Department of Biomedical Research, Nemours Children's Health, Wilmington, DE 19803, USA.
- Department of Pediatrics, Shimane University, Izumo 693-8501, Japan.
- Department of Pediatrics, Graduate School of Medicine, Gifu University, Gifu 501-1193, Japan.
- Department of Pediatrics, Thomas Jefferson University, Philadelphia, PA 19107, USA.
- Department of Biological Sciences, University of Delaware, Newark, DE 19716, USA.
ORCID-Profile: Krishna Sai Musini, Shunji Tomatsu
Förderung
- NICHD NIH HHS
- NIH HHS
- Austrian MPS Society
- A Cure for Robert, Inc.
- The Carol Ann Foundation
- Angelo R. Cali & Mary V. Cali Family Foundation, Inc.
- The Vain and Harry Fish Foundation, Inc.
- The Bennett Foundation
Zitieren
APA
Saikia, S., Musini, K. S., Khan, S., & Tomatsu, S. (2026). Induction of Oral Immune Tolerance Enables Sequential AAV9/AAV8 Gene Therapy in Mucopolysaccharidosis IVA. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27219553
Vancouver
Saikia S, Musini KS, Khan S, Tomatsu S. Induction of Oral Immune Tolerance Enables Sequential AAV9/AAV8 Gene Therapy in Mucopolysaccharidosis IVA. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27219553
BibTeX
@article{Saikia2026,
author = {Saikia, Sampurna and Musini, Krishna Sai and Khan, Shaukat and Tomatsu, Shunji},
title = {Induction of Oral Immune Tolerance Enables Sequential AAV9/AAV8 Gene Therapy in Mucopolysaccharidosis IVA},
journal = {International Journal of Molecular Sciences},
year = {2026},
doi = {10.3390/ijms27219553}
}
EUVIMED